Volume 28, Number 2—February 2022
Dispatch
West Nile Virus Transmission by Solid Organ Transplantation and Considerations for Organ Donor Screening Practices, United States
Table 1
Person | Specimen | DRT | RNA | IgM | Neutralizing antibodies (titer)† | IgG |
---|---|---|---|---|---|---|
Organ donor |
Plasma | −2 | Detected | |||
Serum |
−2 |
Detected |
ND |
ND |
||
Liver recipient |
Serum | 0 | ND | ND | ND | |
Serum | 18 | ND | Detected | Detected (1;2,560) | ||
CSF | 22 | Detected | ||||
Serum |
35 |
ND |
Detected |
|||
Kidney recipient | Serum | 15 | Detected | ND | ||
CSF | 18 | Detected | Detected | |||
Serum | 18 | Detected | Detected | |||
Whole blood | 18 | Detected | ||||
Urine | 18 | Detected | ||||
Serum | 25 | ND | Detected | |||
Whole blood | 25 | Detected |
*Blank cells indicate testing not performed. CSF, cerebrospinal fluid; DRT, day relative to transplantation; ND, not detected. †90% plaque reduction neutralization test result <10 is considered negative.
Page created: November 03, 2021
Page updated: January 22, 2022
Page reviewed: January 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.